Premium
Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models
Author(s) -
Pellegrini C.,
Colucci R.,
Antonioli L.,
Barocelli E.,
Ballabeni V.,
Bernardini N.,
Blandizzi C.,
Jonge W. J.,
Fornai M.
Publication year - 2016
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/nmo.12933
Subject(s) - parkinson's disease , enteric nervous system , neurodegeneration , disease , pathophysiology , neuroscience , medicine , alpha synuclein , gastrointestinal tract , inflammatory bowel disease , gut–brain axis , inflammation , biology , pathology , immunology
Background Symptoms of digestive dysfunction in patients with Parkinson's disease ( PD ) occur at all stages of the disease, often preceding the onset of central motor symptoms. On the basis of these PD ‐preceding symptoms it has been proposed that PD could initiate in the gut, and that the presence of alpha‐synuclein aggregates, or Lewy bodies in the enteric nervous system might represent one of the earliest signs of the disease. Following this hypothesis, much research has been focused on the digestive tract to unravel the mechanisms underlying the onset and progression of PD , with particular attention to the role of alterations in enteric neurotransmission in the pathophysiology of intestinal motility disturbances. There is also evidence suggesting that the development of central nigrostriatal neurodegeneration is associated with the occurrence of gut inflammation, characterized by increments of tissue pro‐inflammatory markers and oxidative stress, which might support conditions of bowel neuromotor abnormalities. Purpose The present review intends to provide an integrated and critical appraisal of the available knowledge on the alterations of enteric neuromuscular pathways regulating gut motor activity both in humans and preclinical models of PD . Moreover, we will discuss the possible involvement of neuro‐immune mechanisms in the pathophysiology of aberrant gastrointestinal gut transit and neuromuscular activity in the small and large bowel.